RTSN logo

Retension Pharmaceuticals Inc.

RTSN
Healthcare|Medical - Pharmaceuticals|US
$11.04
+0.32 (+2.99%)
Next Earnings Report
Dec 2, 2026
EPS est. -$0.49
Financing Filings (last 12 months)
5
Shelf registrations / offering prospectuses — latest Oct 9, 2026 (424B4). Possible dilution.

Upcoming Data Readouts (1)

Mar 2027
Est. completion
P2Uncontrolled Hypertension
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
NCT07142356n=280

Recent Press Releases

Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Nov 5, 2026 · GlobeNewsWire
Retension Pharmaceuticals Announces Pricing of Initial Public Offering
Oct 8, 2026 · GlobeNewsWire

SEC Filings (20)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 23, 20268-KMaterial eventDocumentIndex
Oct 16, 2026SC 13GPassive 5%+ stakeDocumentIndex
Oct 16, 2026SC 13GPassive 5%+ stakeDocumentIndex
Oct 15, 2026SC 13GPassive 5%+ stakeDocumentIndex
Oct 14, 2026SC 13DActivist / 5%+ stakeDocumentIndex
Oct 13, 2026S-8Employee stock planDocumentIndex
Oct 13, 20268-KMaterial eventDocumentIndex
Oct 9, 2026424B4Offering prospectusDocumentIndex
Oct 8, 2026EFFECTDocumentIndex
Oct 8, 2026S-1MEFIPO / offering registrationDocumentIndex
Oct 8, 2026CERTDocumentIndex
Oct 8, 20268-A12BDocumentIndex
Oct 7, 2026S-1/AIPO / offering registrationDocumentIndex
Oct 5, 2026S-1/AIPO / offering registrationDocumentIndex
Sep 18, 2026S-1IPO / offering registrationDocumentIndex
Aug 14, 2026DRS/ADocumentIndex
Jun 16, 2026DRS/ADocumentIndex
May 1, 2026DRS/ADocumentIndex
Feb 17, 2026DRSDocumentIndex
May 6, 2025DDocumentIndex